ViferaXS

ViferaXS

ViferaXS is a clinical-stage biotechnology company developing peptide-based cancer immunotherapies. They focus on hematologic malignancies and solid tumors, with a proprietary T Cell Activator technology. This Series A funding will advance their Phase II trial for chronic lymphocytic leukemia (CLL) and support upcoming Phase I read-outs in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC).

Total raised
Undisclosed
tracked to date
Latest round
Series A
Sep 23, 2026
Known investors
3
led by SPRIND
Press coverage
2
outlets tracked

Is this your company?

Claim this profile to get matched with investors who fund Health startups in Germany.

Claim this profile →

🏆 Featured in Datapile’s Q3 2026 Germany Funding Report

Read the Q3 2026 Germany report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-germany-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 Germany Funding Report</a>

Funding history

  1. 1
    €12 millionSeries ASep 23, 2026

    Led by SPRIND

    Announcement ↗

Founder

Sezai Taskin
Sezai Taskin
CEO

Investors in ViferaXS

Backers from this company's tracked funding rounds.

  • SSPRINDLead investorVC firm
  • HHumaVC firm
  • Pprivate investors

ViferaXS in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile

ViferaXS — Health startup in Tübingen, Germany | Datapile